Thermo Fisher Scientific CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience

Applications and Tested Dilutions

Product Specifications

Additional Formats

• Biotin
• PE
• Request custom conjugation

Product Specific Information

The DJR2-4 monoclonal antibody reacts with human DR5 (also known as TRAIL-R2, Apo2, TRICK2, and KILLER).
DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. It is broadly expressed in normal tissues and several tumor cells.

Applications Reported:
The DJR2-4 (a.k.a. 7-8) antibody is reported for use in flow cytometric analysis.

Applications Tested:
Tested by flow cytometric analysis of human MOLT-4 cell line and DR5-transfected cells.
Recommended use: ≤1 µg per test (100 µL final volume). Cell number may range from 10⁵–10⁸ cells/test.
Optimal performance should be determined by titration.

Purity: >90% (SDS-PAGE)
Aggregation: <10% (HPLC)
Filtration: 0.2 µm post-manufacturing filtered

Target Information

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a death domain-containing receptor for TRAIL, mediating apoptosis through the TNF-receptor superfamily.
It can be activated by TNFSF10/TRAIL/APO-2L and transduces apoptotic signals via FADD adaptor protein.
Two transcript variants and one non-coding transcript have been identified.
Overexpression induces apoptosis and activates NF-kappa-B.
DR5 is expressed in various cell types, notably in lymphocytes and spleen.
Associated diseases include squamous cell carcinoma and diffuse infiltrative lymphocytosis syndrome.

For Research Use Only.
Not for use in diagnostic procedures. Not for resale without express authorization.